[1] |
WANG Dan, REN Jingtian, WU Guizhi, XIONG Weiyi, TANG Ren, PANG Yu, FAN Rong, YANG Le.
Significance of Good Pharmacovigilance Practice in the Construction of China Pharmacovigilance System
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 501-503.
|
[2] |
GENG Hongjiao, WANG Lianxin, XIE Yanming.
Pharmacovigilance of Chinese Medicine in Medical Institutions
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(6): 552-555.
|
[3] |
SA Rina, ZHANG Bing, LIN Zhijian, WANG Xiaofang, ZHANG Xiaomeng.
Pharmacovigilance of Traditional Chinese Medicine in Pharmaceutical Care in Medical Institutions
[J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 422-426.
|
[4] |
FENG Yanan, LIU Xinxin, LI Yonghui, WANG Fang, GUO Ruifeng.
Challenges to Pharmacovigilance by Medical Institutions under the New Drug Administration Law
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(9): 572-573.
|
[5] |
HUANG Yuan, WANG Chenggang, WU Shifu, WANG Ling, TIAN Yuejie, WU Chen, WANG Xiaojun.
Drug Abuse Monitoring Models in Medical Institutions in China
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(9): 607-612.
|
[6] |
WANG Dan, REN Jingtian, DONG Duo, PENG Lili, LIU Wei.
Trend Analysis of Ten-year Annual Reports on Adverse Drug Reaction Monitoring
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(5): 276-283.
|
[7] |
YUAN Lin, GAOYan, LU Changfei.
Preliminary Thinking on the Establishment of Pharmacovigilance System in China
[J]. Chinese Journal of Pharmacovigilance, 2020, 17(11): 749-752.
|
[8] |
SHI Bing-juan.
Thinking on Improving and Guaranteeing the Quality of Traditional Chinese Medicine Preparations in Medical Institutions
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(5): 276-279.
|
[9] |
ZHAO Xia, LENG Meiling, WANG Peng, LI Xinling, CAO Lujuan, TIAN Chunhua, LIU Cuili.
Research on Current Status and Countermeasures of Information Collection on Adverse Drug Reactions by Drug Manufacturers from Medical Institutions in China
[J]. Chinese Journal of Pharmacovigilance, 2018, 15(11): 652-657.
|
[10] |
LI Ang, ZHANG Bing, ZHANG Xiao-meng, SUN Xiao-xia, YANG Xue, LI Fan.
Investigation on the Situation of Cognition and Reporting of Adverse Drug Reactions in 1 109 Basic Medical Institutions
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(5): 289-294.
|
[11] |
DONG Duo ,WU Gui-zhi, WANG Tao, LIU Jia,XIONG Wei-yi,WANG Dan .
The Enlightens on Carrying out Reporting Responsibility of Manufactures in China from Reviewing the Post Marketing Surveillance System in US
[J]. Chinese Journal of Pharmacovigilance, 2017, 14(10): 607-610.
|
[12] |
ZHAO Shi-dan, GAO Xu-guang, DAI Yun-peng, CAO Fei, LIU Li-min, LI Bai-qiang, LU Zhong-ping .
Preliminary Exploration for Construction of Adverse Drug Reaction/Event Sentinel Surveillance in Heilongjiang Province
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(5): 269-271.
|
[13] |
TIAN Chun-hua .
Thinking to Promote Adverse Drug Reaction Monitoring Work of Medical Institutions
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(5): 272-274.
|
[14] |
YU Chao, XU Yu-ming, LI Xin-ling, WANG Ling, ZHOU Juan, WAN Kai-hua, XU Jin, YUAN Xin-dong .
Demand Investigation of Interconnection between Hospital Information System and National Adverse Drug Reaction Monitoring System in China
[J]. Chinese Journal of Pharmacovigilance, 2016, 13(3): 154-158.
|
[15] |
WANG Dan, DONG Duo.
Discussion on the Key Drug Monitoring in China
[J]. Chinese Journal of Pharmacovigilance, 2015, 12(9): 534-537.
|